Moreover, patients with basal-like BC who received neoadjuvant chemotherapy and had low levels of dusp4 expression achieved poorer pathologic complete remission rates and shorter recurrence-free survival periods compared with patients with high levels of dusp4 expression. Here, DUSP4 is linked to breast cancer.